<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03080961</url>
  </required_header>
  <id_info>
    <org_study_id>2015-01</org_study_id>
    <nct_id>NCT03080961</nct_id>
  </id_info>
  <brief_title>The VIBLOK SAfety and perFormancE Trial</brief_title>
  <acronym>SAFE</acronym>
  <official_title>The VIBLOK SAfety and perFormancE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CLJI Worldwide</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Applied Clinical Services BV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rotterdam, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EB FlevoResearch BV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PreCare Trial &amp; Recruitment B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CLJI Worldwide</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Genital herpes has a high prevalence in industrialized as well as developing countries.

      Genital herpes causes genital ulcers, increases risk for acquiring HIV infection, and may be
      transmitted mother to child during birth with possible serious consequences.

      Medical treatments and condoms only partially reduce the risk for transmission from/ to
      sexual partners. Genital herpes transmission despite use of condoms is thought to be due to
      transfer via skin-to-skin contact in unprotected areas, and HSV-2 transmission may be
      enhanced by current shaving habits in the genital area leading to micro lesions (lacerations)
      of the skin.

      VIBLOKâ„¢ is a cream designed to impede the passage of viruses, such as HSV-2, across the skin.
      Bench and animal experiments indicate that it can block virus transmission such as HSV-2 over
      80%.

      The objective of the SAFE trial is to assess the safety and performance of VIBLOK in adults
      with HSV-2 infection by comparing virus detection in the extra-genital area before and after
      application of the barrier cream.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2017</start_date>
  <completion_date type="Actual">November 13, 2017</completion_date>
  <primary_completion_date type="Actual">November 13, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Trial participants take extra-genital swabs before and after application of the barrier cream.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Vials with the sample will be coded. The assessor does not know the coding.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Device Effects</measure>
    <time_frame>26-32 days</time_frame>
    <description>Percentage SADE's in the as treated population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HSV-2 Detection Rate in AT Population</measure>
    <time_frame>26-32 days</time_frame>
    <description>Change in HSV-2 detection rate on days with asymptomatic shedding after applying VIBLOK.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HSV-2 Copy Number in AT Population</measure>
    <time_frame>26-32 days</time_frame>
    <description>Change in HSV-2 copy number on days with asymptomatic shedding after applying VIBLOK.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADE Description</measure>
    <time_frame>1-33 days</time_frame>
    <description>Nature and frequency of (possible) device related adverse events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>HSV-2 Infection</condition>
  <condition>Genital Herpes</condition>
  <arm_group>
    <arm_group_label>Before and after VIBLOK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The degree to which HSV-2 is blocked by the VIBLOK cream is determined by comparing the amount of HSV in the external genital area before and after application of the cream. So participants are their own control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VIBLOK barrier cream</intervention_name>
    <description>VIBLOK safety and performance has not been proven yet in humans with an HSV-2 infection.</description>
    <arm_group_label>Before and after VIBLOK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant is male or female and at least 18 years of age

          2. HSV-2 seropositive by the UW Western blot or Alegria assay

          3. History of recurrent genital herpes with at least 3 recurrences in the last year or,
             if currently on suppressive/ prophylactic therapy, prior to starting the therapy
             (antiviral therapy has to be stopped at least 7 days prior to initiation of the trial
             product).

          4. General good health at the discretion of the investigator.

          5. Willing to not use any topical genital therapy aside from the study device for the
             duration of the trial.

          6. Willing to not use any systemic anti HSV therapy during the entire study starting 7
             days prior to baseline.

          7. Willing to obtain 2 swabs from external-genital areas once daily for the duration of
             the trial.

          8. Willing to keep a daily trial diary during the treatment period.

          9. Negative pregnancy test for women at screening.

         10. Willing to use contraceptives for the duration of the study.

         11. Subject must be willing and able (in the opinion of the investigator) to understand
             the patient information and informed consent form and to comply with the clinical
             trial protocol and procedures.

         12. Subject must be willing to give written informed consent.

        Exclusion Criteria:

          1. Serious medical conditions, such as diabetes, significant autoimmune disease, cancer
             or immunosuppression, etc. that at the discretion of the investigator will likely
             affect study outcomes

          2. Treatment with systemic steroids or other immune-modulating agents

          3. Participation in any investigational drug or device trial within 30 days prior to
             screening.

          4. Pregnancy or breastfeeding, in case of women.

          5. Any other conditions that in the judgment of the investigator would preclude
             successful completion of the clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivienne vd Walle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PreCare Trial &amp; Recruitment B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>EB FlevoResearch</name>
      <address>
        <city>Almere</city>
        <state>Flevoland</state>
        <zip>1311 RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PT&amp;R</name>
      <address>
        <city>Beek</city>
        <state>Limburg</state>
        <zip>6191 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EB UtrechtResearch</name>
      <address>
        <city>Utrecht</city>
        <zip>3511 NH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2017</study_first_posted>
  <results_first_submitted>February 12, 2019</results_first_submitted>
  <results_first_submitted_qc>February 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2020</results_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Barrier cream</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03080961/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03080961/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Upon written informed consent, 82 subjects were enrolled based on their medical history of recurrent genital herpes.</recruitment_details>
      <pre_assignment_details>Of the 82 subjects enrolled, 46 had a confirmed HSV-2 infection and started applying VIBLOK.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>46 subjects with a confirmed HSV-2 infection, took external genital skin swabs before and after applying minimally 0.8 pack (~4 ml) of VIBLOK per swab session.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Adults with recurrent genital herpes due to an HSV-2 infection and that applied VIBLOK at least once.</population>
      <group_list>
        <group group_id="B1">
          <title>As Treated Population</title>
          <description>Participants that applied VIBLOK at least once</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HSV-1 co-infection</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of recurrences past year</title>
          <units>episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years since diagnosis genital herpes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="6.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serious Adverse Device Effects</title>
        <description>Percentage SADE's in the as treated population.</description>
        <time_frame>26-32 days</time_frame>
        <population>46 eligible subjects that applied VIBLOK for an average of 27.2 days.</population>
        <group_list>
          <group group_id="O1">
            <title>During VIBLOK Application</title>
            <description>Percentage SADE's in subjects applying VIBLOK for a minimum of 26 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Device Effects</title>
          <description>Percentage SADE's in the as treated population.</description>
          <population>46 eligible subjects that applied VIBLOK for an average of 27.2 days.</population>
          <units>Percentage SADE's</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>SADE rate after minimally 26 days of VIBLOK treatment will be assessed by calculating the upper limit of the 2-sided exact 95% Clopper-Pearson confidence interval which needs to be below 10%. With a sample size of 36, an exact two-sided 95.0% confidence interval for a single proportion would show that the SADE incidence is below 10% at an expected incidence of 0.1%.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>SADE percentage</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>7.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HSV-2 Detection Rate in AT Population</title>
        <description>Change in HSV-2 detection rate on days with asymptomatic shedding after applying VIBLOK.</description>
        <time_frame>26-32 days</time_frame>
        <population>45 subjects that returned swabs before and after VIBLOK application.</population>
        <group_list>
          <group group_id="O1">
            <title>Before VIBLOK</title>
            <description>Days with HSV detection in the external genital area before application of VIBLOK.</description>
          </group>
          <group group_id="O2">
            <title>After VIBLOK</title>
            <description>Days with HSV detection in the external genital area after application of VIBLOK.</description>
          </group>
        </group_list>
        <measure>
          <title>HSV-2 Detection Rate in AT Population</title>
          <description>Change in HSV-2 detection rate on days with asymptomatic shedding after applying VIBLOK.</description>
          <population>45 subjects that returned swabs before and after VIBLOK application.</population>
          <units>Mean number of swabs with shedding</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.7" upper_limit="4.1"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1.4" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis will evaluate the difference in detection rate between pre and post-VIBLOK swabs. For each person the number of swabs with shedding only pre-VIBLOK will be assessed, and then the number of swabs with shedding only post-VIBLOK will be subtracted. A number above 0 indicates a decreased detection rate after VIBLOK. With an 8% anticipated asymptomatic shedding rate, 80% power, 50 subjects taking samples for 28 days are needed to show a 50% reduction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.248</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HSV-2 Copy Number in AT Population</title>
        <description>Change in HSV-2 copy number on days with asymptomatic shedding after applying VIBLOK.</description>
        <time_frame>26-32 days</time_frame>
        <population>A total of 25 out of 46 subjects in the AT population had days with asymptomatic HSV shedding.</population>
        <group_list>
          <group group_id="O1">
            <title>Before VIBLOK</title>
            <description>HSV amount in external genital swabs on days with asymptomatic shedding before applying VIBLOK.</description>
          </group>
          <group group_id="O2">
            <title>After VIBLOK</title>
            <description>HSV amount in external genital swabs on days with asymptomatic shedding after applying VIBLOK.</description>
          </group>
        </group_list>
        <measure>
          <title>HSV-2 Copy Number in AT Population</title>
          <description>Change in HSV-2 copy number on days with asymptomatic shedding after applying VIBLOK.</description>
          <population>A total of 25 out of 46 subjects in the AT population had days with asymptomatic HSV shedding.</population>
          <units>HSV copy number</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100446.2" lower_limit="24623.8" upper_limit="176268.7"/>
                    <measurement group_id="O2" value="43691.8" lower_limit="1954.4" upper_limit="85429.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADE Description</title>
        <description>Nature and frequency of (possible) device related adverse events.</description>
        <time_frame>1-33 days</time_frame>
        <population>AT Population that applied VIBLOK at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>During VIBLOK Application</title>
            <description>Subjects that applied VIBLOK at least once.</description>
          </group>
        </group_list>
        <measure>
          <title>ADE Description</title>
          <description>Nature and frequency of (possible) device related adverse events.</description>
          <population>AT Population that applied VIBLOK at least once.</population>
          <units>Count of participants per ADE type</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Toxic reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possible allergic reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching/tingling/burning sensation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from the first day of VIBLOK application until 30 days after the last visit to the research clinic.</time_frame>
      <desc>Definitions are applied conform ISO 14155; 2011.</desc>
      <group_list>
        <group group_id="E1">
          <title>During VIBLOK Application</title>
          <description>All AEs were recorded in subjects in all subjects applying VIBLOK at least once until 30 days after the last visit to the research clinic.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other, undefined</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Not-device related infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Toxic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Possible not-device related allergic reaction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Possible device related allergic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Itching/tingling/burning sensation</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>HSV recurrence</sub_title>
                <counts group_id="E1" events="29" subjects_affected="19" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ty Cross, President &amp; CEO</name_or_title>
      <organization>CLJI WORLDWIDE</organization>
      <phone>305-397-8880</phone>
      <email>tycross@cljiworldwide.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

